Crohn's Disease-Associated T Cell Receptor-Related Methods
US-2024112754-A1 · Apr 4, 2024 · US
Pharmaceutical suspension composition
US10238640B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10238640-B2 |
| Application number | US-201615349101-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 11, 2016 |
| Priority date | May 25, 2004 |
| Publication date | Mar 26, 2019 |
| Grant date | Mar 26, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously.
First claim
Opening claim text (preview).
We claim: 1. A thixotropic oral liquid pharmaceutical composition consisting of 0.2 g/100 mL xanthan gum; 1.5 g/100 mL microcrystalline cellulose/carboxymethylcellulose sodium; about 2 g/100 mL ibuprofen; about 28.8 g/100 mL glycerin; 20 g/100 mL sorbitol solution 70%; about 0.2 g/100 mL sucralose; 0.3 g/100 mL polysorbate; about 0.02 g/100 mL chlorpheniramine maleate; about 0.3 g/100 mL pseudoephedrine; about 0.55 g/100 mL sodium citrate; about 0.25 g/100 mL sodium benzoate; about 0.05 g/100 mL edetate disodium; about 0.75 g/100 mL citric acid; flavoring agent; coloring agent; and water. 2. A thixotropic oral liquid pharmaceutical composition consisting of about 2 g/100 mL ibuprofen; 0.2 g/100 mL xanthan gum; 1.5 g/100 mL microcrystalline cellulose/carboxymethylcellulose sodium; about 28.8 g/100 mL glycerin; 20 g/100 mL sorbitol solution 70%; about 0.55 g/100 mL sodium citrate; about 0.05 g/100 mL edetate disodium; about 0.75 g/100 mL citric acid; 0.3 g/100 mL polysorbate; about 0.25 g/100 mL sodium benzoate; about 0.2 g sucralose/100 mL; flavoring agent; and water. 3. A thixotropic oral liquid pharmaceutical composition consisting of 0.2 g/100 mL xanthan gum; about 1.5 g/100 mL microcrystalline cellulose/carboxymethylcellulose sodium; about 1 g/100 mL to about 3 g/100 mL ibuprofen; 0.3 g/100 mL polysorbate; about 0.25 g/100 mL sodium benzoate; about 0.01 g/100 mL to about 0.40 g/100 mL diphenhydramine; about 28.8 g/100 mL glycerin; about 20 g/100 mL sorbitol solution 70%; sucralose; about 0.55 g/100 mL sodium citrate; about 0.05 g/100 mL edetate disodium; about 0.75 g/100 mL citric acid; flavoring agent; and water.
Assignees
Inventors
Classifications
Medicinal preparations containing organic active ingredients · CPC title
- A61K31/4402Primary
only substituted in position 2, e.g. pheniramine, bisacodyl · CPC title
Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006) · CPC title
Carboxylic acids; Salts or anhydrides thereof · CPC title
Dispersions; Emulsions · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10238640B2 cover?
- An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous mediu…
- Who is the assignee on this patent?
- Wyeth Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4402. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).